AstraZeneca PLC

Foreign Filer Report • Dec 1, 2025

6-K 1 a6866j.htm BLOCK LISTING INTERIM REVIEW Document created using Blueprint(R) - powered by Issuer Services - www.issuerservices.net Copyright 2025 Issuer Services a6866j

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of December 2025

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_______

AstraZeneca PLC

INDEX TO EXHIBITS

1. Block listing Interim Review

1 December 2025

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to a PIP .

(Note: Italicised terms have the same meaning as given in the Listing Rules.)

Date : 1 December 2025

| Name of applicant : — Name of scheme: | | ASTRAZENECA PLC — ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA
SAVINGS-RELATED SHARE
OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC
2012 SAVINGS-RELATED SHARE OPTION SCHEME | | |
| --- | --- | --- | --- | --- |
| Period of return: | From: | 1 JUNE 2025 | To: | 30 NOVEMBER 2025 |
| Balance of unallotted securities under scheme(s) from previous
return: | | 3,688,383 | | |
| Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for): | | 0 | | |
| Less: Number
of securities issued/allotted
under scheme(s) during period (see UKLR
20.6.7G): | | 67,907 | | |
| Equals: Balance
under scheme(s) not yet issued/allotted at end of
period: | | 3,620,476 | | |

Name of contact:	Hannah Tattersall
Telephone number of contact:	+44 (0)20 3749 5000

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca

Contacts

For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 01 December 2025

| By: /s/
Matthew Bowden |
| --- |
| Name:
Matthew Bowden |
| Title:
Company Secretary |